ArticleEye (London, England)2019
Biotherapeutics and immunogenicity: ophthalmic perspective.
Article in Eye (London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Targeting angiogenesis: advances in the design and engineered applications of nanobodies.Frontiers in immunology · 2026Review
- Aflibercept 2 mg biosimilar (Tyalia)-real-world experience from IRAN (ATRIA study).Eye (London, England) · 2025Observational
- Prediction of adverse drug reactions using demographic and non-clinical drug characteristics in FAERS data.Scientific reports · 2024Article
- Structure-Based Design of Peptides Targeting VEGF/VEGFRs.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Fear of safety compromise with biosimilar anti-VEGF-perception or truth.Eye (London, England) · 2022Article
- Ranizurel safety evaluation in real-world -(RaSER) study.American journal of ophthalmology case reports · 2022Article
- Future of anti-VEGF: biosimilars and biobetters.International journal of retina and vitreous · 2022Review
- Real-World Safety Outcomes of Intravitreal Ranibizumab Biosimilar (Razumab) Therapy for Chorioretinal Diseases.Ophthalmology and therapy · 2021Article
- Brolucizumab: is extended VEGF suppression on the horizon?Eye (London, England) · 2020Article
- Ophthalmic biosimilars: Lessons from India.Indian journal of ophthalmology · 2019Article
- Medication-induced Uveitis: An Update.Journal of ophthalmic & vision researchArticle
- The Development Pathway for Biosimilar Biotherapeutics.Journal of ophthalmic & vision researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.